

CDER GCP Inspections and Outcomes

Faranak Jamali, MD

Compliance Reviewer, Compliance Enforcement Branch Division of Enforcement and Postmarketing Safety Office of Scientific Investigations/Office of Compliance Center for Drug Evaluation and Research (CDER) U.S. Food and Drug Administration

CDER BIMO Good Clinical Practices (GCP) Compliance and Enforcement – February 16, 2022

Disclaimer



The contents of this presentation are my own and do not necessarily reflect the views and/or policies of the Food and Drug Administration or its staff as per 21 CFR 10.85(k).

Outline



- Inspection process
- Possible outcomes
- Serious non-compliance
- **Case examples**



Corrective and preventive actions

GCP Inspections

Who is Inspected?

- Clinical investigator (CI)
- Sponsor (Sp)

- Contract Research Organization (CRO)

- Sponsor-investigator (SI)
- Institutional Review Board (IRB)







FD/

Purpose of GCP inspections

Inspection process

Possible outcomes

Serious non-compliance

Case examples


Corrective and Preventive Actions





CI Site Selection Factors

- Number of enrolled subjects
- Number of protocol violations
- Discontinuation rate
- Prior GCP history
- Prior inspections and their findings
- Number of INDs




What is reviewed?

- Human subject protection:
 - Informed consent adequacy, IRB approval
- Adherence to the protocol:
 - Eligibility criteria, randomization
 - Blinding, study visits
- Documentation practices; data verification:
 - Key: Primary endpoints, transfer of data into Case Report Forms (CRFs)
- Reporting compliance:
 - To IRB: unanticipated events, change in investigational plan
 - To sponsor: AE's and SAE's, ...







Purpose of GCP inspections

>Inspection process

Possible outcomes

Serious non-compliance


Case examples

Corrective and Preventive Actions

www.fda.gov

Final Inspection Outcome





NAI: No Action Indicated VAI: Voluntary Action Indicated OAI: Official Action Indicated NAI: no violations identified


VAI: violations identified but do not meet the threshold for OAI

OAI: serious noncompliance, repeated or deliberate failure to comply with the regulations



Why should we submit a 483 response?

15 business days



Form FDA 483



May

- Mitigate
- Disprove
- Clarify

Your Written Response

Supporting documentation Your acknowledgement Your commitment

What to consider in your 483 response?

- Submit timely response
- Include a commitment

Address each

- Provide corrective or preventive actions
- Provide timeline
- observation Provide method
- Note: if agree or disagree Submit documentation



Purpose of GCP inspections

>Inspection process

Possible outcomes

Serious non-compliance

Case examples

Corrective and Preventive Actions

Official Action Indicated – OAI



- Significant and serious, and/or numerous regulatory violations
 - Repeated, deliberate
 - Falsified or fabricated data submitted to sponsor or FDA
- Scope, severity, or pattern of violations
 - Unreasonable and significant risk to subjects
 - Subjects' rights seriously compromised
 - Data integrity or reliability compromised



OAI – Warning Letter (WL)

- Available to the public (redacted)
- Informal and advisory
- An opportunity to improve compliance
- Follow-up inspection



OAI – NIDPOE



- The first step in disqualification
- For repeated or deliberate serious noncompliance
- For repeated or deliberate falsification
 - Submitted to FDA or to the sponsor
- Disqualification process initiated

FDA

Follow-up Inspection

✓ To ensure violations are not repeated

- ✓ To verify implementation of corrective/preventive actions
- ✓ To ensure compliance is sustained


~ —	
~ —	
~ —	
 ✓ — 	

CDER BIMO Inspections

FDA


20

CDER BIMO FY 2020



Warning Letters – BIMO

(CDER, FY 2011 - FY 2020)



*Based on letter issue date [Complis database as of Feb 9, 2021].

PMR includes: Accelerated Approval PMR (21 CFR part 314, subpart H); Pediatric Research and Equity Act PMR; Animal Efficacy PMR (21 CFR part 314, subpart I), and FDA Amendments Act PMRs (section 505(o)(3) of the Federal Food Drug & Cosmetic Act).


www.fda.gov

• Sponsor metrics include both Sponsor and Sponsor-Investigator.

Inspectional Findings – CI (CDER, FY 2020)

Domestic CI Deficiencies

Foreign CI Deficiencies




*Based on LogOut Date and Classification. [Complis database as of Feb 9, 2021]. Log out date: Final completion date

** Inspection Activity with Voluntary Action Indicated (VAI) and Official Action Indicated (OAI) Classifications.

www.fda.gov • Note: this does not denote number of inspection activities completed, but rather number of inspection reports evaluated and closed. Inspection activity may have multiple deficiencies.

Frequency of Inspectional Findings: CI – OAI

(CDER, FY 2020)




*Based on letter issue date. [Complis database as of Feb 9, 2021].

• Note: this represents the number of inspection reports evaluated and closed which differs from the number of inspection activities performed. *Inspection activity may have multiple deficiencies.*

FDA

FDA

Inspectional findings – Sponsors (CDER, FY 2020)



Based on final inspection classifications and letter date.

www.fda.gov

Purpose of GCP inspections

>Inspection process

Possible outcomes

Serious non-compliance

Case examples

Corrective and Preventive Actions

www.fda.gov


CI – WL: Failure to Retain Records



- 22 subjects were enrolled and completed the study.
- After study completion, all records were packed into boxes, and placed in archiving room.
- FDA inspection found missing records:
 - All 22 signed/dated consent forms and all case report forms
 - For 16 of 22 randomized: Medical histories, eligibility, adverse events, concomitant meds, progress notes, visit assessments
- 483 Response: Department reorganization contributed to the loss of records.
- WL was issued for failure to retain records.

CI WL – Protocol Violation





FDA

Sponsor WL – Failure to Submit IND

- Sponsor did not submit an IND!
 - An unapproved antiviral drug
 - To subjects with HCV-HIV co-infection
- Sponsor did not ensure proper monitoring!
- 483 response:
 - Sponsor's judgment:
 - The product was not a drug; but a dietary/food supplement.

HCV: hepatitis C virus HIV: Human Immunodeficiency syndrome www.fda.gov 21 CFR 312.2(a) [21 CFR 312.20(a) and 312.40(a) **FD**A

IND Exemption Criteria

• A lawfully marketed drug in U.S.



- Not intended to support a new indication or significant change in labeling or advertising
- Route of administration, dosage, patient population does not significantly increase risk
- For lawfully marketed drugs, not intended to support a significant change in advertisement for the drug





- In compliance with IRB requirements for informed consent
- In compliance with requirements for promotion of the study drug
- A bioavailability or bioequivalence study of an unapproved version of an approved drug product

CI NIDPOE – Data Falsification



- Data falsification after subject's death:
 - Study records falsely documented efficacy endpoint assessments
 - Physical exams, AE assessments, concomitant meds
 - Telephone visits related to primary endpoint
 - False data (primary endpoint) submitted to the sponsor

Purpose of GCP inspections

- >Inspection process
- Possible outcomes
- Serious non-compliance

Case examples

Corrective and Preventive Actions

Some Tips for CAPA



Focus on violations in original OAI		Establish all GCP aspects				Hire Qualified staff	C S ii	Improve Documentation: SOP, work instructions, study worksheets	
Strengthen									
Tra	ain:		Site						
CI	and		Infrastructure			Desi	ign study-		Implement and
study					specific CAPA		Sustain CAPA		
tea	•				spec				

Summary

- Inspection procedures
- Inspected entities: CI/Sp/SI
- Inspection outcome: NAI/VAI/OAI
- Examples of OAI letters



Closing Thought...

- Build high standards for GCP compliance:
 - Proactive compliance
 - Well-articulated protocol
 - Risk identification



Challenge Question



What is usually the most common type of regulatory violation found in clinical investigator inspections?

- A. Record keeping violations
- B. Informed consent violations
- C. Protocol violations
- D. Failure to report unanticipated events to the IRB

References



- U.S. Food and Drug Administration, Investigations Operations Manual 2021
 - <u>https://www.fda.gov/downloads/ICECI/Inspections/IOM/UCM607759.pdf</u>
- U.S. Food and Drug Administration Bioresearch Monitoring Program (BIMO) Compliance Programs
 - <u>https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-program-manual/bioresearch-monitoring-program-bimo-compliance-programs</u>
- U.S. Food and Drug Administration, Regulatory Procedures Manual Chapter 4 Advisory Actions
 - <u>https://www.fda.gov/downloads/ICECI/ComplianceManuals/RegulatoryProceduresManual/UCM074330.</u>
 <u>pdf</u>



Thank you! Questions?